Product image of Metformina + Sitagliptina Tecnigen (Metformin Hydrochloride, Sitagliptin) supplied by GNH India

Metformina + Sitagliptina Tecnigen

Active Ingredient:
Metformin Hydrochloride, Sitagliptin
Origin:
EU

Metformina + Sitagliptina Tecnigen (Metformin Hydrochloride, Sitagliptin)

Metformin hydrochloride, the active ingredient in Metformina + Sitagliptina Tecnigen, is a Biguanide/DPP‑4 inhibitor presented as a tablet for oral use. It is employed to improve blood glucose control in adults with type 2 diabetes mellitus, often in combination with diet, exercise, and other antidiabetic agents.

GNH India supplies Metformina + Sitagliptina Tecnigen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with a focus on quality assurance, regulatory compliance, and reliable logistics for global distribution.

Manufacturer / TM Owner

Pentafarma - Sociedade Tecnico-Medicinal S.A.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Metformina + Sitagliptina Tecnigen is indicated for the management of type 2 diabetes mellitus, targeting hyperglycemia through complementary mechanisms.

  • Type 2 diabetes mellitus: improves glycemic control as monotherapy or in combination with other oral antidiabetics.
  • Adjunct to diet and exercise: enhances the effect of lifestyle interventions in patients whose glucose levels remain elevated.
  • Combination therapy with insulin: provides additional glucose lowering when basal insulin alone is insufficient.

How It Works

  • Metformin reduces hepatic gluconeogenesis and increases peripheral insulin sensitivity, thereby decreasing basal glucose production. Sitagliptin blocks the dipeptidyl peptidase‑4 enzyme, prolonging the activity of incretin hormones (GLP‑1 and GIP) which stimulate glucose‑dependent insulin secretion and suppress glucagon release. The combined action results in lower fasting and post‑prandial blood glucose levels.

Side Effects

Metformina + Sitagliptina Tecnigen may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

  • Nausea
  • Diarrhea
  • Abdominal discomfort
  • Headache
  • Upper respiratory tract infection
  • Mild hypoglycemia (when used with other glucose‑lowering agents)

Serious or Rare Side Effects

  • Lactic acidosis
  • Severe hypoglycemia
  • Acute pancreatitis
  • Allergic reactions (rash, angioedema)
  • Hepatic dysfunction
  • Renal impairment

Precautions & Warnings

When prescribing Metformina + Sitagliptina Tecnigen, clinicians should consider several safety aspects.

  • Renal function assessment: evaluate creatinine clearance before initiating therapy and periodically thereafter.
  • Hepatic impairment: use with caution in patients with liver disease.
  • Risk of lactic acidosis: avoid in conditions predisposing to hypoxia.
  • Pregnancy and lactation: safety not established; consider alternative therapy.
  • Drug interactions: review concomitant medications that affect renal clearance.
  • Store at ambient temperature: keep below 25 °C, protect from moisture and light in original packaging.

Avoid Interactions

Metformina + Sitagliptina Tecnigen can interact with other medicines; some combinations should be avoided while others require monitoring.

Major Interactions (Avoid)

  • Concomitant use with intravenous contrast agents in patients with renal impairment.
  • Combination with other biguanides (e.g., phenformin).
  • Co‑administration with potent CYP2C8 inhibitors (e.g., gemfibrozil) that increase sitagliptin exposure.
  • Use with insulin secretagogues leading to severe hypoglycemia.

Moderate Interactions (Monitor Closely)

  • Concurrent diuretics may affect renal clearance of metformin.
  • Beta‑blockers may mask symptoms of hypoglycemia.
  • ACE inhibitors may increase risk of renal dysfunction.
  • Anticoagulants may require monitoring due to potential alteration in glycemic control.

Frequently Asked Questions

Metformina + Sitagliptina Tecnigen is prescribed to improve blood glucose control in adults with type 2 diabetes mellitus. It can be used as a standalone oral therapy or in combination with other antidiabetic agents, diet, and exercise to achieve target glycemic levels.

Metformin hydrochloride lowers glucose production by the liver and enhances insulin sensitivity in muscle and fat tissue. When combined with sitagliptin, which prolongs incretin hormone activity, the duo provides complementary actions that reduce fasting and post‑meal blood sugar.

The appropriate dose is individualized by the prescribing healthcare professional based on factors such as the patient’s renal function, glycemic targets, and concomitant medications. No fixed regimen can be stated without a prescriber’s assessment.

Safety data for this combination in pregnancy and lactation are limited. It is generally advised to avoid use unless the potential benefit outweighs the potential risk, and alternative therapies should be considered under medical supervision.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with metformin combined with a sulfonylurea, the metformin‑sitagliptin combo offers a lower risk of hypoglycemia because sitagliptin enhances insulin secretion only when glucose is elevated. It also provides a convenient fixed‑dose option, whereas sulfonylureas act independently of glucose levels.

The tablets should be stored at ambient temperature, preferably below 25 °C, in their original blister pack or container. Protect them from excess moisture, heat and direct sunlight to maintain stability throughout the shelf life.

The medication is taken orally, usually once daily with or without food, as directed by the prescriber. Swallow the tablet whole with a glass of water; do not crush or chew unless specifically instructed.

The most critical adverse events include lactic acidosis (particularly in patients with renal or hepatic impairment), severe hypoglycemia when used with other glucose‑lowering agents, and acute pancreatitis. Prompt medical attention is required if any of these conditions are suspected.

Patients with severe renal impairment (eGFR <30 mL/min/1.73 m²), known hypersensitivity to metformin or sitagliptin, or a history of lactic acidosis should avoid this medication. It is also contraindicated in individuals with uncontrolled heart failure or acute metabolic acidosis.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Metformin Hydrochloride, Sitagliptin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT